Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1978 May 27;1(6124):1402–1404. doi: 10.1136/bmj.1.6124.1402

Bromocriptine in Parkinsonism.

I Pearce, J M Pearce
PMCID: PMC1604749  PMID: 348261

Abstract

A review of the effects of using bromocriptine in Parkinson's disease showed that it rarely helps patients not primarily improved by levodopa. Patients who show late failure with levadopa and whose response to treatment is declining are helped by combining the two drugs. High cost and severe psychosis are the main disadvantages of bromocriptine, and, although it is not recommended for patients who are doing well on levodopa, it is the best available drug for hospital use in patients who show late failure with levodopa.

Full text

PDF
1402

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gerlach J. Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial. Acta Neurol Scand. 1976 Mar;53(3):189–200. doi: 10.1111/j.1600-0404.1976.tb04337.x. [DOI] [PubMed] [Google Scholar]
  2. Godwin-Austen R. B., Smith N. J. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1977 May;40(5):479–482. doi: 10.1136/jnnp.40.5.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hunter K. R., Shaw K. M., Laurence D. R., Stern G. M. Sustained levodopa therapy in parkinsonism. Lancet. 1973 Oct 27;2(7835):929–931. doi: 10.1016/s0140-6736(73)92595-6. [DOI] [PubMed] [Google Scholar]
  4. Johnson A. M., Loew D. M., Vigouret J. M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br J Pharmacol. 1976 Jan;56(1):59–68. doi: 10.1111/j.1476-5381.1976.tb06959.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kartzinel R., TEYCHENNE P., Gillespie M. M., Perlow M., Gielen A. C., Sadowsky D. A., Calne D. B. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet. 1976 Aug 7;2(7980):272–275. doi: 10.1016/s0140-6736(76)90728-5. [DOI] [PubMed] [Google Scholar]
  6. Lees A. J. Bromocriptine. Br J Hosp Med. 1977 Oct;18(4):336, 341-2. [PubMed] [Google Scholar]
  7. Lieberman A., Kupersmith M., Estey E., Goldstein M. Treatment of parkinson's disease with bromocriptine. N Engl J Med. 1976 Dec 16;295(25):1400–1404. doi: 10.1056/NEJM197612162952504. [DOI] [PubMed] [Google Scholar]
  8. Parkes J. D., Debono A. G., Marsden C. D. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1101–1108. doi: 10.1136/jnnp.39.11.1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pearce J., Pearce I. Current concepts of Parkinsonism. Postgrad Med J. 1971 Dec;47(554):794–799. doi: 10.1136/pgmj.47.554.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pearce J., Pearce I. Letter: Parkinsonism and dementia: effects of levodopa. Lancet. 1975 May 31;1(7918):1245–1245. doi: 10.1016/s0140-6736(75)92238-2. [DOI] [PubMed] [Google Scholar]
  11. Sachdev Y., Gomez-Pan A., Tunbridge W. M., Duns A., Weightman D. R., Hall R., Goolamali S. K. Bromocriptine therapy in acromegaly. Lancet. 1975 Dec 13;2(7946):1164–1168. doi: 10.1016/s0140-6736(75)92655-0. [DOI] [PubMed] [Google Scholar]
  12. Shoulson I., Glaubiger G. A., Chase T. N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975 Dec;25(12):1144–1148. doi: 10.1212/wnl.25.12.1144. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES